


Information from the Canadian Hematology Society

re: ISH 2018 Vancouver Meeting

Program Details



Sept 13, 2018	
1	08:30 - 10:00 Venous Thromboembolic Disease HIT and DIC: Unraveling Ischemic Limb Injury Causes Ted Warkentin, Canada Management of Cancer-Associated Thrombosis Cynthia Wu, Canada
2	10:30 - 12:00 Plasma Cell Disorders - 1 Antibody Therapies in Multiple Myeloma Kevin Song, Canada Understanding the Genetic Changes in Myeloma Brian Walker, USA Modern Management of AL-Amyloidosis Kevin Song, Canada
SS1 13:30 - 15:00 ISH-ASH Joint Symposium: Targeted Therapies in Hematology Gene Inhibitor Therapy in AML Donna Hogge, Canada JAK inhibition in chronic MPDs Ruben Mesa, USA CRISPR/Cas9 Genome Editing in Hemoglobinopathies Fabien Touzot, Canada	
SS2 15:15 - 16:15 Special Hematology Session: Nuclear Terrorism Nuclear Terrorism Robert Gale, USA	
17:15 OC 17:15 - 17:45 Opening Ceremony	



Dr. Tom Nevill

**Scientific Program
Committee Chair**

September 14, 2018			
08:30 - 10:00	3A Acute Myelogenous Leukemia Prognostic Stratification in AML Roland Walter, USA Germline Mutations Associated with Myeloid Neoplasms Akiko Shimamura, USA Determining Optimal Treatment for AML Patients Andre Schuh, Canada	3B Acquired Coagulopathies Treatment of Acquired Hemophilia A Rebecca Kruse-Jarres, USA Managing the Hemostatic Defects of Massive Transfusion Syndrome Andrew Shih, Canada Controlling Hemorrhage in a Patient with Liver Disease Jody Kujovich, USA	3C Developments in Apheresis One TMA: Current Approaches & Management of TTP Gail Rock, Canada Stem Cell Mobilization Strategies Gayatri Sreenivasan, Canada Extracorporeal Photopheresis for Treatment of Graft-versus-Host Disease Raewyn Broady, Canada
10:30 - 12:00	4A Stem Cell and Telomere Biology What We Know About AML Stem Cells Donna Hogge, Canada Telomeres and telomerase in normal and malignant hematopoiesis Peter Lansdorp, Canada	4B Inherited Bleeding Disorders Antibody Therapy in Hemophilia Guy Young, USA Molecular Genetics of Von Willebrand's Disease David Lillicrap, Canada Management of the Undefined Bleeding Disorder Shannon Jackson, Canada	4C Aggressive Non Hodgkin Lymphoma Checkpoint Inhibitors in Lymphoma Kerry Savage, Canada The Role of Autologous Stem Cell Transplantation in Management of Primary CNS Lymphoma Doug Stewart, Canada Management of Double and Triple-Hit Lymphomas David Scott, Canada
13:30 - 15:00	5A Chronic Lymphocytic Leukemia Pathogenesis & Risk Factors for CLL Cynthia Toze, Canada Which therapy is Best for del(17p) CLL: Ibrutinib or Venetoclax Alina Gerrie, Canada Where Does Allogeneic Transplantation Fit in the Management of CLL? Cynthia Toze, Canada	5B Advances in Hemoglobinopathies Treatment Hydroxyurea, Transfusions & Supportive Care in Sickle Cell Anemia Nancy Robitaille, Canada Allogeneic Stem Cell Transplant Hemoglobinopathies Christina Peters, Austria New therapies in β Thalassemia Richard Ward, Canada	5C Benign Cytopenias Controversies in the Management of ITP Adrian Newland, USA Clonal Hematopoiesis in Congenital Neutropenia/G-CSF in Cyclic Neutropenia David Dale, USA
15:30 - 17:00	6A Hodgkin Lymphoma Will Brentuximab Vedotin & Nivolumab Improve Survival in Relapsed/Refractory Hodgkin Lymphoma? Alina Gerrie, Canada Treatment of Grey Zone Lymphomas Joseph Connors, Canada Is There a Role for Allogeneic Stem Cell Transplantation in Hodgkin Lymphoma? John Kuruvilla, Canada	6B Chronic myeloid leukemia Choosing the Best Frontline Agent in CML Jeff Lipton, Canada Molecular Mechanisms in CML: From Transformation to TKI Discontinuation Pierre Laneuville, Canada When is it Safe to Discontinue TKIs? Donna Forrest, Canada	6C Eosinophils, Mast cells & Histiocytes New Insights into the Molecular Genetics of Non-Langerhans Histiocytosis Julien Haroche, France Management of Mast cell Disease: Indolent, Smoldering & Aggressive Animesh Pardanani, USA Eosinophilic diseases Luke Chen, Canada
17:00 - 18:00	SS3 Special Session: Case Presentations Case Presentations Thomas Nevill, Canada Case Presentations Monika Hudoba, Canada	MTE1 Meet-the-Expert Session • Treatment of Post-Autograft Relapse of Hodgkin Lymphoma Treatment of Post-Autograft Relapse of Hodgkin Lymphoma Joseph Connors, Canada	MTE2 Meet-the-Expert Session • HIT Heparin-induced thrombocytopenia (HIT) Ted Warkentin, Canada

September 15, 2018

08:30 - 10:00	7A Advances in Allogeneic Stem Cell Transplantation Post-transplantation Cyclophosphamide in Unrelated Donor SCT Marco Mielcarek, USA Is Haploidentical Transplantation the Way of the Future? Robert Gale, USA	7B Obstetric Hematology Treatment of Lymphoma in Pregnancy Joseph Connors, Canada Management of Thrombocytopenia in Pregnancy Leslie Zypchen, Canada Can We Agree on Optimal Management of Mantle Cell Lymphoma John Kuruville, Canada BRAF Inhibitors in Hairy Cell Leukemia Michael Grever, USA	7C Transfusion Medicine Transfusion Outcomes After Short and Long-Term Blood Storage Ted Warkentin, Canada Thresholds for Red Cell and Platelet Transfusions in Acute Leukemia Patients Andrew Shih, Canada Transfusion-Related Acute Lung Injury: Risk factors, Management & Prevention Tanya Petraszko, Canada
10:30 - 12:00	8A / Red Cell Disorders Management of Pure Red Cell Aplasia Robert Means, USA Megaloblastic Anemias: Why Are They Still Important? Ralph Green, USA A Practical Approach to Hyperferritinemia Luke Chen, Canada	8B / Indolent Lymphoproliferative Disorders Novel Therapies for Follicular Lymphoma Laurie Sehn, Canada Can We Agree on Optimal Management of Mantle Cell Lymphoma John Kuruville, Canada BRAF Inhibitors in Hairy Cell Leukemia Michael Grever, USA	8C / Acute Lymphoblastic Leukemia - 1 New Insights into the Genetics of Childhood ALL Kirk Schultz, Canada CAR T-cell Therapy in ALL Shannon Maude, USA
13:30 - 15:00	9A Plasma Cell Disorders - 2 Developing a Rational Approach to the Treatment of Multiple Myeloma Joseph Mikhael, USA Overview of IgG-4 Disease Mollie Carruthers, Canada Monoclonal Gammopathy with Renal Significance Joseph Mikhael, USA	9B Bone Marrow Failure GATA2 mutation disorders/Telomeropathies Thomas Nevill, Canada Therapeutic Options for LGL Leukemia Thomas Loughran, USA Etiology, Pathogenesis & Initial Therapy of Aplastic Anemia Phillip Scheinberg, Brazil	9C Hematology in the Developing World Improving the Outcomes for Leukemia & Lymphoma in Developing Countries David Gómez-Almaguer, Mexico Helminthic Disease of the Lungs in Immunocompromised Patients Alissa Wright, Canada Systematic Analysis of Global Anemia & Global Epidemiology of Hemoglobinopathies Nicholas Kassebaum, USA
15:30 - 17:00	10A Myelodysplastic syndromes The role of next generation sequencing in prognosis Rafael Bejar, USA Novel therapies in low and high-risk MDS Mikhael Sekeres, USA Management of Iron Overload in MDS Heather Leitch, Canada	10B Laboratory Hematology Laboratory Investigation of Disorders of Platelet Function Catherine Hayward, Canada MRD Testing by Flow Cytometry in AML Roland Walter, USA Hemoglobinopathies - Screening and Diagnostics Nicholas Au, Canada	10C Congenital Hematological Disorders Diagnosis and Management of Gaucher Disease Dominick Amato, Canada Familial Hemophagocytic Lymphohistiocytosis David Dix, Canada Fanconi Anemia: Genetics and Clinical Implications Şule Unal, Turkey
17:00 - 18:00	MTE3 Meet-the-Expert Session: Deciding on Post-Transplant Maintenance in Multiple Myeloma Deciding Post-Transplant Maintenance in Multiple Myeloma Joseph Mikhael, USA	SS4 Morphology Session Sample Cases of Newly Defined Entities in the WHO 2016 Classification of Hematological Malignancies Aysegül Uner, Turkey	MTE4 Meet-the-Expert: Management of Aplastic Anemia Unresponsive to Cyclosporine/ATGAM Management of Aplastic Anemia Unresponsive to Cyclosporine/ATGAM Phillip Scheinberg, Brazil

September 16, 2018

07:30 - 08:30	MTE5 Meet-the-Expert : The Problematic ITP patient - Current management and future treatment options The Problematic ITP patient - Current management and future treatment options Adrian Newland, USA	MTE6 Meet-the-Expert Session: Treatment of MDS with a High-risk Molecular Profile Treatment of MDS with a High-risk Molecular Profile Mikhael Sekeres, USA	
08:30 - 10:00	11A Complement Disorders New Genetic Insights and Evolving Therapies for Paroxysmal Nocturnal Hemoglobinuria Christopher Patriquin, Canada Diagnosis and Management of aHUS Gayatri Sreenivasan, Canada Complement Activation in Anti-Phospholipid antibody Syndrome Christopher Patriquin, Canada	11B Myeloproliferative Disorders Polycythemia Vera: Approach to Treatment Lynda Foltz, Canada Prognostic Factors in Myelofibrosis and Essential Thrombocytosis Ruben Mesa, USA	11C Organizing a BMT Unit in Underprivileged Circumstances General Guidelines Robert Gale, USA Experience in Turkey Emin Kansu, Turkey Organizing a BMT unit in underprivileged circumstances: Experience in Mexico Guillermo Ruiz-Argüelles, Mexico
10:30 - 12:00	12A Disorders of Platelet Number and Function Genomics to Uncover Novel Inherited Platelet Disorders Jacob Rozmus, Canada Causes and Consequences of Constitutional Platelet Dysfunction Catherine Hayward, Canada	12B Autologous Stem Cell Transplantation Autologous SCT for Multiple Sclerosis Natasha Kekre, Canada Cell Dose Thresholds for Autologous SCT Maryse Power, Canada	12C Acute Lymphoblastic Leukemia - 2 Antibody Therapies in ALL Elias Jabbour, USA
10:30 - 12:00	Closing Session: Key Take-Home Messages Key Take-Home Messages		